Search Results for “AI” – Page 604 – media

Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA

Kite, a Gilead Company, announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.
- Source: Businesswire
- 679
- October 20, 2017
B-cell lymphoma CAR–T FDA Market Views Yescarta
H7N9 influenza is both lethal and transmissible in animal model for flu

For the first time, Kawaoka says, his team has identified an influenza virus strain that is both transmissible between ferrets (the best animal model proxy for human influenza infections) and lethal, both in the animal originally infected and in otherwise healthy ferrets in close contact with these infected animals.
- Source: Medicalxpress
- 977
- October 20, 2017
H7N9 Researches
China’s Cardiovascular Drugs Import and Export Report

Cardiovascular drugs are medicines used to treat medical conditions associated with the heart or the circulatory system (blood vessels), such as arrhythmias, blood clots, coronary artery disease, high or low blood pressure, high cholesterol, heart failure, and strokes, whose therapeutic effects aim to improve cardiac functions, regulate blood flow of heart and change the circulatory system of blood distribution among other things.
- Source: Ddu
- 1,548
- October 19, 2017
cardiovascular Market Reports
GlaxoSmithKline wins first-ever nod for blockbuster vaccine prospect Shingrix

Just as GlaxoSmithKline nears a decision from the U.S. FDA for its key shingles vaccine, Shingrix, Canada has become the first country to approve the shot—and it's a key piece of CEO Emma Walmsley's prescription for growth at the drugmaker.
- Source: fiercepharma
- 607
- October 19, 2017
New Approvals shingles vaccine
U.S. pressing India to avoid capping medical device prices, allow withdrawals

Indian Prime Minister Narendra Modi’s government has in recent months slashed prices of medical devices such as knee implants and heart stents by up to 75 percent to make them more affordable.
- Source: reuters
- 436
- October 19, 2017
Market Views medical device
Hormone therapy for prostate cancer increases cardiac risk

Androgen-deprivation therapy, which is a common treatment for prostate cancer, has been tentatively linked with an increased risk of cardiovascular disease. A new study solidifies these concerns.
- Source: medicalnewstoday
- 612
- October 19, 2017
cancer cardiovascular prostate Researches
FDA Okays Another CAR T-Cell Therapy

The FDA has approved a second chimeric antigen receptor (CAR) T-cell therapy for cancer: Kite Pharma's axicabtagene ciloleucel (Yescarta) for the treatment of certain types of refractory large B-cell lymphoma, the agency announced.
- Source: medpagetoday
- 747
- October 19, 2017
cancer CAR–T FDA New Approvals
Ddu to Attend the CPhI Worldwide

The International Pharmaceutical Networking Exhibition (CPhI Worldwide 2017), will be held at Ludwig-Erhard-Anlage 1 in Messe Frankfurt, Germany from the 24th to the 26th of October 2017. As the leading global pharmaceutical & medical device B2B online platform, Ddu is going to attend the exhibition, showcasing the new Chinese cross-border medical trade method to Germany and the whole world.
- Source: Ddu
- 1,077
- October 19, 2017
CPhI Exhibitions & Activities
AstraZeneca admits cancer data for acquired drug was fabricated

AstraZeneca has revealed that early-stage data concerning the efficacy of its acquired drug acalabrutinib in the treatment of blood cancers and solid tumours was invented and falsified.
- Source: Pharmafile
- 638
- October 19, 2017
acalabrutinib AstraZeneca blood cancer solid tumour
Takeda and HemoShear Therapeutics Enter into Exclusive Drug Discovery Partnership in Liver Diseases

Takeda Pharmaceutical Company Limited and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a partnership to discover and develop novel therapeutics for liver diseases, including nonalcoholic steatohepatitis (NASH).
- Source: finance.yahoo
- 442
- October 18, 2017
Company Insight NASH therapeutics

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.